O
10.27
-0.85 (-7.64%)
| 前收盘价格 | 11.12 |
| 收盘价格 | 11.06 |
| 成交量 | 3,236,189 |
| 平均成交量 (3个月) | 3,622,518 |
| 市值 | 2,187,997,696 |
| 价格/销量 (P/S) | 26.47 |
| 股市价格/股市净资产 (P/B) | 7.02 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业利益率 (TTM) | -597.47% |
| 稀释每股收益 (EPS TTM) | -1.11 |
| 季度收入增长率 (YOY) | -27.60% |
| 总债务/股东权益 (D/E MRQ) | 28.66% |
| 流动比率 (MRQ) | 10.22 |
| 营业现金流 (OCF TTM) | -145.46 M |
| 杠杆自由现金流 (LFCF TTM) | -87.96 M |
| 资产报酬率 (ROA TTM) | -27.21% |
| 股东权益报酬率 (ROE TTM) | -57.19% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Ocular Therapeutix, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.25 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.82% |
| 机构持股比例 | 87.01% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Summer Road Llc | 30 Sep 2025 | 12,579,657 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 21.00 (HC Wainwright & Co., 104.48%) | 购买 |
| 21.00 (Chardan Capital, 104.48%) | 购买 | |
| 中 | 21.00 (104.48%) | |
| 低 | 20.00 (Needham, 94.74%) | 购买 |
| 平均值 | 20.67 (101.27%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 16.06 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 09 Dec 2025 | 21.00 (104.48%) | 购买 | 15.95 |
| 05 Nov 2025 | 21.00 (104.48%) | 购买 | 10.81 | |
| HC Wainwright & Co. | 08 Dec 2025 | 21.00 (104.48%) | 购买 | 16.11 |
| 25 Nov 2025 | 19.00 (85.00%) | 购买 | 12.13 | |
| Needham | 08 Dec 2025 | 20.00 (94.74%) | 购买 | 16.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合